🫀🧿🙏🧬💝 Proud to be part of this dedicated team, working hard to implement impactful strategies in our fight against #atherosclerosis & its risk factors. #EAS European Atherosclerosis Society Borge G Nordestgaard Lale Tokgozoglu Katariina Öörni Jeanine RvL Prof Kausik Ray FMedSci EVANGELOS LIBEROPOULOS Stefano Romeo

Great talk, Lale Tokgozoglu! 🧿🌷🙏 Her key message is one we should never forget: Middle age is already too late to take action on LDL lowering European Atherosclerosis Society

What a great chance to exchange knowledege and expanding horizons through partnership with latin amerincan peers and European Atherosclerosis Society. Huge congrats to the organizers. Looking forward to many future collaborations #CardioTwitter #Cardiology #Colesterol Borge G Nordestgaard Prof Kausik Ray FMedSci

Big news! The #EASStage will debut at the EAS Congress in Glasgow! Come and join us—we're getting ready to bring something exciting! We’re gearing up for #EASStage at the EAS Congress in Glasgow! Stay tuned for updates on what’s coming. #EAS2025 #LipidScience #Cardiology #EAS

Are you on #SoMe? At EAS Congress plan to attend a pannel on how to best harness social media to benefit your carreer! #SoMe ambassadors are planning an interactive session on site and online. Bookmark it in your calendar, the informationtime and schedule will soon be available.

We are proud to have participated in the 1st #EASLATAM Congress in Cartagena 🇨🇴 — a groundbreaking event that united LATAM with European Atherosclerosis Society . - The event was marked by deep discussions, true collaboration, & a powerful EAS presence in the region. - Thanks to all the #EASLATAM

🆕 ESC Updated the Level of Evidence Grading System (Part I: Therapy & Prevention) The European Society of Cardiology has revised its LOE grading system to address previous limitations. The new approach offers clearer, standardized criteria based on study quality, sample size, robustness against

sinus venosus ASD #whyCMR #cardioTwitter Benay Ozbay

Join us #ACC25 in the #CVPrevention session tomorrow Eugenia Gianos MD Prof Kausik Ray FMedSci Dr Meral Kayikcioglu Borge G Nordestgaard Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Erin D. Michos, M.D. Pam R. Taub, MD❤️💃🏻 Jeanine RvL

⏰The clock is ticking on regular rates! Secure your spot at #EASCongress2025 before the deadline and be part of the key discussions shaping the future of cardiovascular science. Register now🔗 bit.ly/3UYJAKF #CardiovascularHealth #HeartHealthExperts

🌍 On this World Health Day, we're excited to share that EAS is now on BlueSky - alongside our current profiles! Follow eas.to/EASBlueSky for the latest in atherosclerosis research, education & global health updates💙 Prof Kausik Ray FMedSci Katariina Öörni

#EASCongress is all about learning and meeting people. This year, we’re focusing even more on the networking part. Make sure to download our app - we’re launching a great new feature that helps you connect with others who share your interests, before, during, and after the event.

Great debate: Plasma triglycerides are an important causal factor and therapeutic target for atherosclerotic cardiovascular disease: Jan Boren+Chris Packard vs. Børge Nordestgaard. academic.oup.com/eurheartj/adva… Who wins? Here are the arguments - you decide - open acces

Since 2016 and the Improve It trial we have known that two drugs statins and ezetimibe combination therapy were better than statin monotherapy after an MI for CVD prevention. We also have had PCSK9i trials showing other combination therapies also reduce CVD when added to statins.

Honored to speak at the Riga Lipid Conference 2025— I presented on “Homozygous FH: Clinical Approach and International Registries,” highlighting insights from global data and the importance of collaboration in rare lipid disorders. A heartfelt thank you to Prof. Gustavs

This week, I saw a young woman who developed xanthelasma after pregnancy, during the puerperium period. #Pregnancy in FH pts often means prolonged exposure to high cholesterol due to interrupted treatment—reminding us that these “windows” carry lifelong atherosclerotic burden.